Phase II trial of all-trans retinoic acid in metastatic non-small cell lung cancer

Cancer Investigation

Volumn 14, Issue 5, 1996, Pages 415-420

  Treat, Joseph ^a   Friedland, David ^a   Luginbuhl, William ^a   Meehan, Lorraine ^a   Gorman, Genevieve ^a   Miller Jr , Wallace ^a   Bavaria, Joseph ^a   Kaiser, Larry ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HEADACHE; HUMAN; LEUKOCYTOSIS; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY;

EID: 0029843973     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909609018898     Document Type: Article

References (36)

1. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer - Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988.
2. Souquet PJ, Chauvin F, Boissel JP, et al: Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet 342:19-21, 1993.
3. Bollag W: Vitamin A and vitamin A acid in the prophylaxis and therapy of epithelial tumors. Int J Vitamin Res 40:299-314, 1990.
4. Bollag W: Retinoids and cancer. Cancer Chemother Pharmacol 3:207-215, 1979.
5. Lotan R: Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem Biophys Acta 605:33-91, 1980.
6. Sporn MB, Dunlop NM, Newton DL, et al: Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs. Fed Proc 35:1332-1338, 1976.
7. Warrell R, Frankel S, Miller W, et al: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324:1385-1393, 1991.
8. Yung WKA, Scott C, Fischbach AJ, et al: All trans-retinoic acid: A phase II radiation therapy oncology group study (RTOG-9113) in patients with recurrent malignant astrocytoma. Proc ASCO 495, 13:176, 1994.
9. Winer E, Sutton L, Petros W, et al: Phase II trial of all-trans retinoic acid (TRA) in patients (PTS) with metastatic breast cancer. Proc ASCO 46, 13:61, 1994.
10. Athanasiadis I, Gradishar W, Sheehan T, et al: A phase II study of all-trans retinoic acid and interferon-alpha (IFN-α) in patients with advanced non-small cell lung cancer (NSCLC). Proc ASCO 1090, 13:330, 1994.
11. Grunberg S, Itri L: Phase II study of isoretinoin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 71(11): 1097-1098, 1987.
12. Rinaldi DA, Lippman SM, Burris HA III, et al: 13-cis-retinoic acid and interferon-alpha 2a in patients with advanced squamous cell lung cancer. Anticancer Drugs 4:33-36, 1993.
13. Arnold A, Ayoub J, Douglas L, et al: Phase II trial of 13 cis-retinoic acid plus interferon α in non-small-cell lung cancer. J Natl Cancer Inst 86:306-309, 1994.
14. Ryssel HJ, Brunner KW, Bollag W: Die perorale anwendung von Vitamin A-saure bei leukoplakien, hyperkeratosen und plattenepithelkarzinomen. Schweiz Med Wochenschr 101:1027-1030, 1971.
15. Lippman SM, Meyskens FL Jr: Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 107:499-502, 1987.
16. Toma S, Palumbo R, Gustavino C, et al: Efficacy of the association of 13-cis-retinoic acid (13cRA) and interferon-α2a (IFNα2a) in cervical intraepithelial neoplasia (CIN II-III): A pilot study. Proc ASCO 815, 13:258, 1994.
17. Evard JP, Bollag W: Konservative hehandlung der rezidivierenden harnblasenpapillomatose mit Vitamin A-saure. Schweiz Med Wochenschr 102:1880-1883, 1972.
18. Reynolds C, Mattlay K, Croose U, et al: Response of neuroblastoma bone marrow metastases to 13 cis-retinoic acid. Proc Am Soc Clin Oncol 9:54, 1990.
19. Lippman S, Parkinson D, Itri L, et al: 13-cis-retinoic acid and interferon alpha-2a: Effective conbination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 84:235-241, 1992.
20. Lippman S, Kavanagh J, Paredes-Espinoza M, et al: 13-cis-retinoic acid plus interferon-alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 84:241-245, 1992.
21. Hong W, Lippman S, Itri L, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801, 1991.
22. Pastorino U, Infante M, Maioli M, et al: Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol 11:1216-1222.
23. Percy C, Horm JW, Goffman TE: Trends in histologic type of lung cancer. SEER Program, 1973-1981. In: Lung Cancer: Causes and Prevention, edited by M Mizell, P Dorrea, Deerfield Beach, FL, Verlag, Chemie International, 1984, p 153.
24. Kurzrock R, Estey E, Talpaz M: All-trans retinoic acid: Tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 11:1489-1495, 1993.
25. Kahn M, Luginbuhl W, Gaines L, et al: Leucocytosis associated with all-trans retinoic acid treatment in metastatic non-small cell lung cancer. J Natl Cancer Inst 84:1669, 1992.
26. Lee J, Newman R, Lippman S, et al: Phase I evaluation of all-trans-retinoic acid in adults with solid tumors. J Clin Oncol 11:959-966, 1993.
27. Neel B, Gebert J, Moghal N, et al: Abnormalities in retinoic acid receptor beta (RAR beta) are common in human lung cancer. Lung Cancer 6 (S6):199, 1990.
28. Gebert JF, Moghal N, Frangioni JV, et al: High frequency of retinoic acid receptor abnormalities in human lung cancer. Oncogene 6:1859-1868, 1991 [published erratum appears in Oncogene 7:821, 1992].
29. Kok K, Osinga J, Carritt, et al: Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature 330:578-581, 1987.
30. Athanasiadis I: Personal communication, 1994.
31. Guchelaar HJ, Timmar-Bosscha H, Dam-Mairing A, et al: Enhancement of cisplatin and etoposide cytotoxicity after all-trans retinoic acid-induced cellular differentiation of a murine embryonal carcinoma cell line. Int J Cancer 55:442-447, 1993.
32. Brazzell R, Vane F, Ehmann C, et al: Pharmacokinetics of isotretinoin during repetitive dosing to patients. Eur J Clin Pharmacol 24:695-702, 1983.
33. Muindi J, Frankel SR, Miller WH Jr, et al: Continuous treatment with all-trans retinoic acid causes a progressive decrease in plasma concentrations:Implications for relapse and "resistance" in acute promyelocytic leukemia. Blood 79:299-303, 1992.
34. Leo MA, Iida S, Lieber CS: Retinoic acid metabolism by a system reconstituted with cytochrome P-450. Arch Biochem Biophys 234: 305-312, 1984.
35. Rigas JR, Francis PA, Muindi JRF, et al: Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 85:1921-1926, 1993.
36. Newman RA, Lee JS, Lippman SM, et al: Phase I evaluation of all-trans-retinoic acid (TRA) combined with ketoconazole (KTC) in adults with solid tumors. Proc ASCO 367, 13:143, 1994.